Skip to main content
An official website of the United States government

Immune features of precancer progression: Insights from the HTAN Precancer Atlas

DCP Immunology Interest Group Seminar

Please join us for a discussion on Immune features of precancer progression: Insights from the HTAN Precancer Atlas DCP Immunology Interest Group Seminar with Shelley Hwang, MD, MPH

 

Key information

  • Date: Wednesday, March 11, 2026
  • Time: 12:00pm EDT to 1:00pm EDT
  • Location: Virtual

Shelley Hwang, MD, MPH

Mary and Deryl Hart Distinguished Professor of Surgery
Vice-Chair of Research, Department of Surgery
Professor of Radiology
Core Faculty Member, Duke-Margolis Institute for Health Policy
Member of the Duke Cancer Institute
Duke University

Dr. Shelley Hwang is the Mary and Deryl Hart Professor of Surgical Oncology, Vice Chair of Research in the Department of Surgery, and Director of the Breast Cancer Program for the Duke University Comprehensive Cancer Center. Her research focus includes breast cancer prevention, identifying less invasive treatments for early-stage breast cancers including ductal carcinoma in situ (DCIS), and understanding the genetic and stromal determinants of cancer progression. Dr. Hwang is an experienced clinical trialist with an interest in the treatment of early-stage breast cancer including DCIS. She is lead investigator (PI) of a national cooperative group study through the ALLIANCE evaluating the role of active surveillance, de-escalating surgery for low-risk DCIS. She serves as Co-Chair of the National Cancer Institute Breast Cancer Steering Committee (BCSC) and member of the NCCN Screening Guidelines Committee. Other interests of the Hwang Lab include the evolutionary role of tumor and environmental heterogeneity in driving DCIS progression and the impact of the breast density, microenvironmental factors, and the stromal immune infiltrate in determining breast cancer phenotype and response to chemotherapy. Her team incorporates computational models of cancer progression, and has developed progression models for invasive breast cancer. In 2016 she was honored by TIME magazine for her contributions to improving quality of life for patients diagnosed with breast cancer. Her work has been supported by the NIH, NCI, DoD, PCORI, Komen, Cancer Research UK, and the Breast Cancer Research Foundation.

For more information 

  • about this seminar, please contact Sidney Fu
  • about the NCI DCP Immunology Interest Group and the IIG Seminar Series please contact Anda Vlad, MD PHD